University of Ulm

uni-ulm.de

Total trials

143

Active

29

Phase 3

15

Total enrollment

94,525

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 7 of 7 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Cytarabine10
Daunorubicin5
venetoclax2
Standard chemotherapy2
CPX-3511
Immunoglobulins1
Application of exosomes in a whole blood assay1

Next readouts

  • 2025-07-31
  • 2027-06
  • 2027-09-01
  • 2029-03

Top conditions

  • Acute Myeloid Leukemia12
  • Amyotrophic Lateral Sclerosis6
  • Acute Myeloid Leukemia (AML)6
  • Coronary Artery Disease6
  • Sepsis4
  • Critically Ill4
  • Iron Deficiency3
  • SIRS3

Frequently asked questions about University of Ulm

How many clinical trials does University of Ulm have on ClinicalTrials.gov?
University of Ulm is listed as the lead sponsor on 143 clinical trials in ClinicalTrials.gov, 29 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Ulm's trials are in Phase 3?
15 of University of Ulm's trials are in Phase 3, spread across 7 active drug programs.
What therapeutic areas does University of Ulm focus on?
University of Ulm's most-studied conditions on ClinicalTrials.gov are Acute Myeloid Leukemia, Amyotrophic Lateral Sclerosis, Acute Myeloid Leukemia (AML), Coronary Artery Disease, Sepsis.
When are University of Ulm's next clinical trial readouts?
University of Ulm has 4 upcoming primary-completion readouts tracked here; the soonest is “Immune Modulation by Exosomes in COVID-19”, expected around 2025-07-31.